文献速递神经免疫

视网膜神经节细胞层厚度与临床孤立综合征患者未来疾病活动的关联

Association of Retinal Ganglion Cell Layer Thickness With Future Disease Activity in Patients With Clinically Isolated Syndrome.
PubMed 文献 · JAMA Neurol · 2018-01-01

这项前瞻性纵向队列研究在德国2个中心纳入97例临床孤立综合征患者,中位随访729天,发现视网膜神经节细胞及内丛状层厚度最薄三分位组未达到NEDA-3的风险是最厚三分位组的3.33倍,低鼻侧视网膜神经纤维层厚度亦与未达NEDA-3相关。

要点

  • 视网膜神经节细胞及内丛状层厚度最薄组未达NEDA-3风险为最厚组的3.33倍。
  • 该厚度最薄组随访诊断多发性硬化风险为最厚组的4.05倍。
  • 低鼻侧视网膜神经纤维层厚度与未达NEDA-3相关(HR 2.46)。

核心结论

  • 视网膜神经节细胞及内丛状层厚度可能成为预判临床孤立综合征患者未来疾病活动和多发性硬化诊断的有价值影像标志物,或有助于患者监测和启动疾病修饰治疗。

研究设计与样本

  • 前瞻性纵向队列研究,2011年1月至2017年5月在德国2个三级转诊中心开展,筛查179例临床孤立综合征患者,最终纳入97例(54.2%),中位随访729天。

主要发现

  • 97例患者中58例(59%)随访期间未达到NEDA-3标准。
  • 视网膜神经节细胞及内丛状层厚度最薄三分位组较最厚三分位组未达NEDA-3的HR为3.33(95%CI 1.70-6.55;P<.001;log-rank P=.001)。
  • 视网膜神经节细胞及内丛状层厚度最薄三分位组较最厚三分位组随访诊断多发性硬化的HR为4.05(95%CI 1.93-8.50;P<.001)。
  • 鼻侧视网膜神经纤维层厚度最薄三分位组较最厚三分位组未达NEDA-3的HR为2.46(95%CI 1.29-4.66;P=.01;log-rank P=.02)。
  • 内丛状层厚度和T2加权病灶计数与未达NEDA-3无关联。

关键数值与推荐

  • NEDA-3标准:未达到无疾病活动证据标准为主要结局。
  • 多发性硬化诊断采用2010年McDonald标准。
  • 视网膜神经节细胞及内丛状层厚度最薄三分位组未达NEDA-3的HR为3.33(95%CI 1.70-6.55)。
  • 视网膜神经节细胞及内丛状层厚度最薄三分位组诊断多发性硬化的HR为4.05(95%CI 1.93-8.50)。
  • 鼻侧视网膜神经纤维层厚度最薄三分位组未达NEDA-3的HR为2.46(95%CI 1.29-4.66)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinically isolated syndrome (CIS) describes a first clinical incident suggestive of multiple sclerosis (MS). Identifying patients with CIS who have a high risk of future disease activity and subsequent MS diagnosis is crucial for patient monitoring and the initiation of disease-modifying therapy. OBJECTIVE: To investigate the association of retinal optical coherence tomography (OCT) results with future disease activity in patients with CIS. DESIGN, SETTING, AND PARTICIPANTS: This prospective, longitudinal cohort study took place between January 2011 and May 2017 at 2 German tertiary referral centers. A total of 179 patients with CIS were screened (80 in Berlin and 99 in Munich). Patients underwent neurological examination, magnetic resonance imaging (MRI), and OCT. Only eyes with no previous optic neuritis were considered for OCT analysis. MAIN OUTCOMES AND MEASURES: The primary outcome was not meeting the no evidence of disease activity (NEDA-3) criteria; secondary outcomes were MS diagnosis (by the 2010 McDonald criteria) and worsening of disability. The primary measure was OCT-derived ganglion cell and inner plexiform layer thickness; the secondary measures included peripapillary retinal nerve fiber layer thickness, inner nuclear layer thickness, and MRI-derived T2-weighted lesions. RESULTS: A total of 97 of the 179 screened patients (54.2%) were enrolled in the study at a median of 93 (interquartile range [IQR], 62-161) days after a first demyelinating event. The median follow-up duration (Kaplan-Meier survival time) was 729 (IQR, 664-903) days. Of 97 patients with CIS (mean age 33.6 [7.9] years; 61 [62.9%] female), 58 (59%) did not meet NEDA-3 criteria during the follow-up period. A Kaplan-Meier analysis showed a significant probability difference in not meeting NEDA-3 criteria by ganglion cell and inner plexiform later thickness (thinnest vs thickest tertile: hazard ratio [HR], 3.33 [95% CI, 1.70-6.55; P < .001; log-rank P = .001). A follow-up diagnosis of MS was more likely for patients with low ganglion cell and inner plexiform layer thickness (thinnest vs thickest tertile: HR, 4.05 [95% CI, 1.93-8.50]; P < .001). Low peripapillary retinal nerve fiber layer thickness likewise indicated risk of not meeting NEDA-3 criteria (thinnest vs thickest tertile: HR, 2.46 [95% CI, 1.29-4.66]; P = .01; log-rank P = .02). Inner nuclear layer thickness and T2-weighted lesion count were not associated with not meeting NEDA-3 criteria. CONCLUSIONS AND RELEVANCE: Retinal ganglion cell and inner plexiform layer thickness might prove a valuable imaging marker for anticipating future disease activity and diagnosis of MS in patients with CIS, which can potentially support patient monitoring and initiation of disease-modifying therapy.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Zimmermann HG, Knier B, Oberwahrenbrock T, et al. Association of Retinal Ganglion Cell Layer Thickness With Future Disease Activity in Patients With Clinically Isolated Syndrome. JAMA Neurol. 2018. PMID: 29710121. doi:10.1001/jamaneurol.2018.1011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。